Sign in
CYPH Stock Price, Chart, Stats & News
Cypherpunk Technologies Inc.
Save
36.98M
Market cap
–
Current P/E
–
Forward P/E
CYPH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -9631.58% |
Operating margin | -19649.28% |
Pretax margin | 4821.53% |
Net margin | -8537.80% |
Effective tax rate | 52.15% |
ROA | -10.94% |
ROE | -16.90% |
D/E | 0.00x |
Interest coverage ratio | -1711.13x |
CYPH valuation
P/E | – |
P/S | 177.98x |
P/B | 0.28x |
P/CF | -0.49x |
P/FCF | -0.41x |
P/OCF | -0.49x |
PEG | -0.02x |
EV multiple | -1.27x |
About
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development.
Similar securities
Based on sector and market capitalization
Report issue